sorafenib has been researched along with Experimental Hepatoma in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (5.00) | 29.6817 |
| 2010's | 51 (85.00) | 24.3611 |
| 2020's | 6 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, J; Jiang, J; Kang, J; Li, E; Li, L; Liu, B; Peng, Y; Wang, Q; Wang, Y; Wu, J; Yang, Q; Yu, W; Zhang, J | 1 |
| Chen, D; Goh, WH; Soh, CK; Wang, H | 1 |
| Chen, M; Cheng, CL; Chin, DW; Law, CT; Lee, D; Lee, JM; Ng, IO; Shen, J; Tsang, FH; Wei, L; Wong, CC; Wong, CM | 1 |
| Bai, H; Hu, X; Phan, C; Tang, G; Wang, J; Wang, Q; Zheng, Z | 1 |
| Alseth, I; Aukrust, P; Berges, N; Bjørås, M; Dahl, TB; Fladeby, C; Gregersen, I; Halvorsen, B; Holm, S; Klungland, A; Kong, XY; Nawaz, MS; Quiles-Jiménez, A; Segers, F; Suganthan, R; Vågbø, C; Vik, ES | 1 |
| Bian, Y; Guo, D | 1 |
| Chen, Y; Huang, Y; Li, X; Wang, J; Xu, L; Yu, H; Zhang, F; Zhuge, Y; Zou, X | 1 |
| Chang, CC; Chen, Y; Chou, MC; Dinh, TK; Huang, JK; Huang, KW; Jan, JJ; Ke, YY; Lee, CJ; Shia, KS; Shiue, TY; Song, JS; Sung, YC; Ta, YN; Wu, CH; Yeh, KC; Yeh, TK | 1 |
| Gonda, K; Inose, T; Ishida, T; Kamei, T; Kato, C; Kitamura, N; Miyagi, S; Nishimura, R; Ohta, M; Tada, H; Takano-Kasuya, M; Une, N; Unno, M | 1 |
| Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD | 1 |
| Han, JK; Kim, JH; Lee, JH; Lee, S | 1 |
| Hayashi, Y; Machihara, K; Murakami, I; Namba, T; Tanaka, H | 1 |
| Chen, B; Dai, HT; Huang, YH; Li, N; Lin, R; Liu, N; Tang, KY; Yang, JY | 1 |
| Chang, CJ; Cheng, AL; Chiu, CJ; Hsu, CH; Liang, CW; Liao, CC; Lu, LC; Yang, YH | 1 |
| Asha, VV; Isaac, R; Jiji, SG; Philip, S; Praseetha, PK; Tom, G | 1 |
| Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
| Duan, W; Liu, Y | 1 |
| Chai, CY; Chiang, CM; Chiou, SS; Hsu, SH; Huang, SK; Liu, KY; Wang, LT; Wang, SN; Yokoyama, KK | 1 |
| Li, H; Shi, Y; Yang, C; Zhao, L | 1 |
| Al-Abdulla, R; Andersen, JB; Avila, MA; Banales, JM; Briz, O; Geier, A; Lozano, E; Macias, RIR; Marin, JJG; Martinez-Chantar, ML; Monte, MJ; O'Rourke, CJ; Serrano, MA | 1 |
| Chacon, E; Cornea, V; Eman, P; Garcia, C; Gedaly, R; Jiang, J; Liu, C; Marti, F; Spear, B; Turcios, L; Watt, DS | 1 |
| Cai, J; Shen, Z; Wu, B; Zhang, W | 1 |
| Li, G; Zhao, L | 1 |
| Dai, Z; Fan, J; Gu, F; Huang, X; Jiang, J; Tan, C; Wang, Z; Xu, M; Yan, J; Zhou, J | 1 |
| Chen, MH; Chen, ML; Cheng, AL; Lu, WC; Yan, BS; Yang, PC; Yu, SL | 1 |
| Dufour, JF; Erös de Bethlenfalva-Hora, C; Geier, A; Kettenbach, J; Mertens, JC; Piguet, AC; Schmitt, J; Terracciano, L; Weimann, R | 1 |
| Baron Toaldo, M; Bolondi, L; Cipone, M; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
| Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H | 1 |
| Liu, X; Shi, G; Wang, L; Wang, Q; Wu, R | 1 |
| Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE | 1 |
| Arnold, B; Augustin, HG; Bergeest, JP; Géraud, C; Goerdt, S; Hu, J; Komljenovic, D; Mogler, C; Neumann, A; Rohr, K; Runge, A; Schirmacher, P; Wieland, M | 1 |
| Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM | 1 |
| Bogaerts, E; Colle, I; Descamps, B; Devisscher, L; Geerts, A; Janssens, S; Lambrecht, BN; Laukens, D; Libbrecht, L; Paridaens, A; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vanhove, C; Verhelst, X | 1 |
| Alvarez-Barrientos, A; Bertran, E; Cepeda, EB; Fabra, À; Fabregat, I; Fernández-Rodríguez, CM; Fernández-Salguero, P; Fernando, J; Giannelli, G; Malfettone, A; Raimondi, G; Sancho, P; Vilarrasa-Blasi, R | 1 |
| Chi, H; Meng, Z; Wang, H; Wang, P; Xu, L; Zhu, X | 1 |
| Guo, QQ; Wang, QD; Yang, GR; Zhao, YL | 1 |
| Dauch, D; Eilers, M; Geffers, R; Hohmeyer, A; Kang, TW; Laufer, S; Leibold, J; Longerich, T; Lowe, SW; Malek, NP; McJunkin, K; Pesic, M; Powers, S; Rudalska, R; Schirmacher, P; Sipos, B; von Thun, A; Weiss, KH; Wuestefeld, T; Zender, L; Zuber, J | 1 |
| Cao, H; Chen, L; Chen, Y; Gu, W; He, X; Huang, Y; Li, Y; Wang, Y; Xu, M; Yin, Q; Yu, H; Zhang, Z | 1 |
| Altomonte, J; Braren, R; Dworniczak, J; Ebert, O; Esposito, I; Feuchtinger, A; Groß, C; Heid, I; Heß, J; Rummeny, E; Sayyed, S; Schlitter, AM; Schwaiger, M; Settles, M; Steiger, K; Steingötter, A; Unger, K; Walch, A; Zitzelsberger, H | 1 |
| Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW | 1 |
| Barbero-Camps, E; Bárcena, C; Colell, A; de Gregorio, E; Fernandez-Checa, JC; García-Ruiz, C; Marí, M; Martinez-Nieto, GA; Morales, A; Moutinho, C; Stefanovic, M; Tutusaus, A; Villanueva, A | 1 |
| Jiang, D; Liu, Y; Wang, T; Xiao, Y; Yang, S; Yu, D; Zhang, B; Zhang, J; Zhang, N | 1 |
| Kim, do Y; Kim, GM; Kim, MD; Kim, SH; Lee, do Y; Park, SI; Shin, M; Shin, W; Won, JY | 1 |
| Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL | 1 |
| Elsadek, B; Kratz, F; Mansour, A; Saleem, T; Warnecke, A | 1 |
| Anderson, DG; Conte, D; Fischer, A; Hough, S; Kennedy, Z; Li, Y; Moore, J; Mou, H; Park, A; Pomyen, Y; Song, CQ; Thorgeirsson, S; Wang, XW; Weng, Z; Xue, W; Yin, H; Zender, L | 1 |
| Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC | 1 |
| Choo, SP; Chow, P; Chung, A; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Soo, KC; Thng, CH | 1 |
| Oseini, AM; Roberts, LR | 1 |
| Alsinet, C; Bruix, J; Cabellos, L; Chiang, DY; Deniz, K; Fiel, MI; Friedman, SL; Hoshida, Y; Lim, KH; Llovet, JM; Mazzaferro, V; Melgar-Lesmes, P; Minguez, B; Newell, P; Peix, J; Roayaie, S; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tovar, V; Villanueva, A; Yea, S | 1 |
| Kerbel, RS; Lee, CR; Man, S; Tang, TC; Xu, P | 1 |
| Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
| Emmenegger, U; Francia, G; Hashimoto, K; Kerbel, RS; Man, S; Tang, TC; Xu, P | 1 |
| Afthinos, M; Djonov, V; Dufour, JF; Hlushchuk, R; McSheehy, PM; Piguet, AC; Radojevic, V; Saar, B; St-Pierre, MV; Terracciano, L | 1 |
| Carr, BI; Cavallini, A; D'Alessandro, R; Refolo, MG; Wang, M; Wang, Z | 1 |
| Chang, C; Hsu, CL; Huang, CK; Hung, YC; Jeng, LB; Lin, TY; Ma, WL; Wu, MH; Yeh, CC; Yeh, S | 1 |
| Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O | 1 |
| Bouzin, C; Calderon, PB; Charette, N; Danhier, P; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J; Magat, J; Mignion, L; Sonveaux, P; Starkel, P; Verrax, J | 1 |
| Anmarkrud, JA; Huitfeldt, HS; Line, PD; Liu, SZ; Scholz, H; Shi, JH; Wierød, L; Zhang, SJ | 1 |
| Huang, GL; Liu, GJ; Lü, MD; Wang, W; Xie, XH; Xie, XY; Xu, M; Xu, ZF; Zheng, SG; Zheng, YL | 1 |
1 review(s) available for sorafenib and Experimental Hepatoma
| Article | Year |
|---|---|
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Embryonic Development; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Proteins; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sorafenib | 2009 |
59 other study(ies) available for sorafenib and Experimental Hepatoma
| Article | Year |
|---|---|
Discovery of an Orally Active and Liver-Targeted Prodrug of 5-Fluoro-2'-Deoxyuridine for the Treatment of Hepatocellular Carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Deoxyuridine; Drug Discovery; Liver; Liver Neoplasms, Experimental; Mice; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2016 |
Design, Synthesis, and Preclinical Evaluation of Fused Pyrimidine-Based Hydroxamates for the Treatment of Hepatocellular Carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
Topics: Animals; Antineoplastic Agents; Carbazoles; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; High Mobility Group Proteins; Histone Chaperones; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Sorafenib; Transcription Factors; Transcriptional Elongation Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclodextrins; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Molecular Chaperones; Optical Imaging; Positron-Emission Tomography; Solubility; Sorafenib | 2019 |
Deletion of Endonuclease V suppresses chemically induced hepatocellular carcinoma.
Topics: Adenosine; Animals; Antineoplastic Agents; Carcinogenesis; Cell Line; Deoxyribonuclease (Pyrimidine Dimer); Gene Expression; Humans; Inosine; Liver; Liver Neoplasms, Experimental; Mice, Knockout; RNA Editing; RNA, Transfer; Sequence Analysis, RNA; Sorafenib | 2020 |
Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Curcumin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drug Tolerance; Hep G2 Cells; Humans; Injections, Intravenous; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Particle Size; Sorafenib; Surface Properties | 2020 |
Preparation of microspheres encapsulating sorafenib and catalase and their application in rabbit VX2 liver tumor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Catalase; Cell Line, Tumor; Chemoembolization, Therapeutic; Drug Compounding; Female; Hydrogen Peroxide; Liver Neoplasms, Experimental; Male; Microspheres; Necrosis; Polylactic Acid-Polyglycolic Acid Copolymer; Rabbits; Sorafenib; Tumor Hypoxia; Tumor Microenvironment | 2020 |
A highly selective and potent CXCR4 antagonist for hepatocellular carcinoma treatment.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Diethylnitrosamine; Drug Synergism; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lymphocytes, Tumor-Infiltrating; Male; Mice; Molecular Docking Simulation; Rats; Receptors, CXCR4; Signal Transduction; Sorafenib; T-Lymphocytes, Cytotoxic; Tumor Microenvironment; Tumor-Associated Macrophages; Xenograft Model Antitumor Assays | 2021 |
The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors.
Topics: Angiogenesis Inhibitors; Animals; Blood Vessels; Carcinoma, Hepatocellular; Female; Liver Neoplasms, Experimental; Mice, Inbred BALB C; Phenylurea Compounds; Quinolines; Sorafenib; Tumor Hypoxia; X-Ray Microtomography | 2021 |
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Disease Progression; Enzyme Activation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperthermia, Induced; Liver Neoplasms, Experimental; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vitamin K 1; Xenograft Model Antitumor Assays | 2017 |
Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Sorafenib | 2018 |
Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Oxazines; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship | 2017 |
The earlier, the better: the effects of different administration timepoints of sorafenib in suppressing the carcinogenesis of VEGF in rats.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Drug Administration Schedule; Heterografts; Immunohistochemistry; Liver Neoplasms, Experimental; Mice, Inbred BALB C; Mice, Nude; Microvessels; Rats; Rats, Sprague-Dawley; Sorafenib; Survival Analysis; Time Factors; Up-Regulation; Vascular Endothelial Growth Factor A | 2018 |
Targeting tumor-infiltrating Ly6G
Topics: Animals; Antibodies, Neutralizing; Antigens, Ly; Antineoplastic Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Interleukin-6; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Myeloid Cells; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Biological Availability; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetite Nanoparticles; Male; Neoplasm Proteins; Niacinamide; Particle Size; Phenylurea Compounds; Polyvinyl Alcohol; Rats; Rats, Wistar; Sorafenib | 2018 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Monosaccharides; Nanoparticles; Sorafenib; Structure-Activity Relationship | 2018 |
TIP60-dependent acetylation of the SPZ1-TWIST complex promotes epithelial-mesenchymal transition and metastasis in liver cancer.
Topics: Acetylation; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Bevacizumab; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Lysine Acetyltransferase 5; Mice; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Nuclear Proteins; Protein Interaction Mapping; Protein Processing, Post-Translational; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transcription Factors; Twist-Related Protein 1; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Interactions; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Exosomes; Heat-Shock Proteins; Humans; Liver Neoplasms, Experimental; Mesenchymal Stem Cells; Mice, Inbred BALB C; RNA, Small Interfering; Sorafenib | 2018 |
Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; CHO Cells; Cricetulus; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Gene Expression Profiling; Gene Silencing; HEK293 Cells; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Octamer Transcription Factor-1; Rats; Rats, Wistar; RNA, Messenger; Sorafenib | 2019 |
Autophagic flux modulation by Wnt/β-catenin pathway inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autophagy; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gene Knockdown Techniques; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Sorafenib; Sulfonamides; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2019 |
pH-responsive hyaluronic acid nanoparticles coloaded with sorafenib and cisplatin for treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Membrane Permeability; Cell Survival; Cisplatin; Delayed-Action Preparations; Drug Liberation; Drug Therapy, Combination; Hep G2 Cells; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Liver Neoplasms; Liver Neoplasms, Experimental; Mice, Nude; Nanocapsules; Sorafenib | 2019 |
Sorafenib-loaded hydroxyethyl starch-TG100-115 micelles for the treatment of liver cancer based on synergistic treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Delivery Systems; Hydroxyethyl Starch Derivatives; Liver Neoplasms, Experimental; Mice, Nude; Micelles; Phenols; Polyethylene Glycols; Pteridines; Rats; Rats, Sprague-Dawley; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; Liver Transplantation; Male; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred ACI; Rats, Inbred Lew; Sorafenib; Tissue Array Analysis | 2013 |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Flow Cytometry; Liver Neoplasms, Experimental; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Tumor Microenvironment | 2014 |
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Hepatocyte Growth Factor; Interleukin-10; Liver Neoplasms, Experimental; Macrophages; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta; Vascular Endothelial Growth Factors | 2014 |
Early prediction of treatment response to sorafenib with elastosonography in a mice xenograft model of hepatocellular carcinoma: a proof-of-concept study.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Elasticity Imaging Techniques; Female; Heterografts; Liver; Liver Neoplasms, Experimental; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Burden | 2013 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib | 2014 |
Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Liver; Liver Neoplasms, Experimental; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Rats; Rats, Wistar; Sorafenib; Tomography, Emission-Computed; Treatment Outcome | 2014 |
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib; Vorinostat; Xenograft Model Antitumor Assays | 2014 |
An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Humans; Liver Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Models, Biological; NF-kappa B p50 Subunit; Niacinamide; Organophosphates; Phenanthrenes; Phenylurea Compounds; Prodrugs; Signal Transduction; Sincalide; Sorafenib; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2014 |
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response | 2014 |
A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Hyaluronan Receptors; Liver Neoplasms, Experimental; Mice, Nude; Niacinamide; Phenotype; Phenylurea Compounds; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2015 |
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms, Experimental; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Signal Transduction; Snail Family Transcription Factors; Sorafenib; Transcription Factors | 2014 |
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Xenograft Model Antitumor Assays | 2014 |
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
Topics: Activating Transcription Factor 2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 14; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2014 |
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopharmaceutics; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Mice; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Disease Models, Animal; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Sorafenib | 2015 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53 | 2015 |
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Ceramides; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucosyltransferases; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Delivery Systems; Drug Liberation; Female; Gadolinium; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Mice; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Treatment Outcome; Tumor Burden | 2016 |
Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Feasibility Studies; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms, Experimental; Male; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Tissue Distribution; Vascular Endothelial Growth Factor A | 2016 |
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magnetic Resonance Imaging; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Microwaves; Necrosis; Neoplasm, Residual; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Ultrasonography | 2016 |
The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diethylnitrosamine; Doxorubicin; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms, Experimental; Male; Niacinamide; Phenylurea Compounds; Rats; Rats, Wistar; Serum Albumin; Sorafenib; Survival Rate | 2017 |
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Topics: Animals; Benzimidazoles; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Cytoskeletal Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Neurofibromatosis 1; Genome-Wide Association Study; Hepatocytes; High-Throughput Nucleotide Sequencing; HMGA Proteins; HMGA2 Protein; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Nude; Mitogen-Activated Protein Kinases; Nerve Tissue Proteins; Niacinamide; Nitriles; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; ras Proteins; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2017 |
Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models.
Topics: Animals; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Heterografts; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Cell Line, Tumor; Liver Neoplasms, Experimental; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sirolimus; Sorafenib | 2009 |
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Synergism; Female; Gene Dosage; Genes, ras; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinases; Pyridines; ras Proteins; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2009 |
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Doxorubicin; Female; Humans; Injections, Subcutaneous; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tegafur; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2010 |
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Liposomes; Liver Neoplasms, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Time Factors; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2010 |
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carrier Proteins; Cell Proliferation; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Intracellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphoproteins; Pyridines; Random Allocation; Rats; Sirolimus; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Diethylnitrosamine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-raf; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; Vitamin K 1 | 2011 |
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Random Allocation; Receptors, Androgen; Sorafenib; Tumor Cells, Cultured | 2012 |
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Division; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-3; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Benzamides; Blotting, Western; Diphenylamine; Electron Spin Resonance Spectroscopy; Fibrosarcoma; Glutathione; Liver Neoplasms, Experimental; Mice; Neoplasms, Experimental; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Sorafenib | 2012 |
RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorescent Antibody Technique; Hepatectomy; Hepatocytes; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Molecular Targeted Therapy; Neoplasm Micrometastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Rats; Sorafenib | 2013 |
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Topics: Animals; Antineoplastic Agents; Catheter Ablation; Combined Modality Therapy; Disease Progression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |